Business
Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product License for SmoothX; Radiographic Barium Contrast Suspension
(TheNewswire) Calgary, Alberta – TheNewswire - Feb...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of Product License for SmoothX; Radiographic Barium Contrast Suspension\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire -\n \n \n February 12, 2021\n \n \n –\n \n \n Voyageur Pharmaceuticals\nLtd.\n \n \n (\n \n \n TSXV\n \n \n :\n \n \n VM\n \n \n )\n \n \n USA\n \n \n (OTC\n \n \n :\n \n \n \n VYYRF)\n \n \n \n (the \"Company\"\nor \"Voyageur\")\n \n \n is pleased to announce\nthat it has received approval from Health Canada for SmoothX.  \nSmoothX is a barium radiographic contrast suspension that is\nspecifically formulated for computed tomography procedures (CT Scans).\n  This approval authorizes the sale of SmoothX for use in radiology\nprocedures in Canada.   SmoothX is specifically designed for use on\nCT Scans of the abdomen and gastrointestinal tract in both adults and\npediatric patients.\n \n \n \n \n Voyageur has four additional barium radiographic\ncontrast Products that are currently under review by Health Canada and\nwe expect product licences to be forthcoming.\n \n \n \n \n “Voyageur’s business plan has always been to launch\nBarium Contrast Radiographic Suspension products into the Canadian\nmarketplace initially, then pursue other markets. This approval is the\ncritical milestone to allow our company to transition to a cash\nflowing pharmaceutical company” reports Brent Willis, Voyageur’s\nCEO.\n \n \n \n \n Voyageur has a strategic plan to advance through the\nstart-up phase of formulating, final testing of product and then\nmanufacturing.  This is expected to lead to full production\nmanufacturing, sales and distribution of barium contrast products\nnationally in the near term.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur Pharmaceuticals Ltd. is Canadian public\ncompany listed on the TSX Venture Exchange under the trading symbol\nVM. Voyageur is focused on the development of barite, iodine, and\nfullerene Active Pharmaceutical Ingredient (API) minerals. The\nnear-term focus is developing barium, iodine radio-contrast products\nand fullerene-based pharmaceutical products.\n \n \n \n \n Voyageur’s goal is to initially generate the positive\ncash flow from operations using third party GMP pharmace...